Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Burning Rock Biotech (BNR) EBITDA: 2019-2025

Historic EBITDA for Burning Rock Biotech (BNR) over the last 7 years, with Sep 2025 value amounting to $17.6 million.

  • Burning Rock Biotech's EBITDA rose 417.23% to $17.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.1 million, marking a year-over-year decrease of 117.64%. This contributed to the annual value of -$47.0 million for FY2024, which is 48.61% up from last year.
  • Burning Rock Biotech's EBITDA amounted to $17.6 million in Q3 2025, which was up 181.39% from -$21.6 million recorded in Q2 2025.
  • Burning Rock Biotech's EBITDA's 5-year high stood at $572.9 million during Q4 2022, with a 5-year trough of -$210.8 million in Q3 2022.
  • Its 3-year average for EBITDA is -$17.3 million, with a median of -$21.6 million in 2025.
  • The largest annual percentage gain for Burning Rock Biotech's EBITDA in the last 5 years was 1,394.41% (2022), contrasted with its biggest fall of 722.71% (2022).
  • Over the past 5 years, Burning Rock Biotech's EBITDA (Quarterly) stood at -$44.3 million in 2021, then skyrocketed by 1,394.41% to $572.9 million in 2022, then plummeted by 31.44% to $392.8 million in 2023, then crashed by 102.67% to -$10.5 million in 2024, then surged by 417.23% to $17.6 million in 2025.
  • Its EBITDA stands at $17.6 million for Q3 2025, versus -$21.6 million for Q2 2025 and -$13.6 million for Q1 2025.